Certara Inc

Certara Inc

CERT · NASDAQ · Healthcare / Health Information Services

11.57USD-0.33 (-2.77%)

Price History

Full chart

Market Stats

Previous Close11.90
Open12.02
Day Range11.55 – 12.18
52-Week Range4.45 – 13.88
Volume2.67M
Market Cap1.36B
P/E (TTM)0.00
Forward P/E27.17
EPS-0.14
Dividend Yield0.00%
Beta1.41
50-Day Avg8.00
200-Day Avg7.18

About

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Jon Resnick
  • Employees1.51K
  • Headquarters4 Radnor Corporate Center, Radnor, PA, United States, 19087, USA
  • Websitehttps://www.certara.com

Leadership

  • Dr. Robert P. Aspbury Ph.D.President of Certara Predictive Technologies · b. 1972
  • Mr. Leif E. PedersenSenior Advisor · b. 1965
  • Dr. Adrian K. McKemey Ph.D.President of Drug Development Solutions
  • Mr. Jon ResnickCEO & Director · b. 1973
  • Mr. Julien PerrierPresident & Chief Commercial Officer
  • Mr. Faiz MohammedInterim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer · b. 1973
  • Dr. Christopher Bouton Ph.D.Chief Technology Officer & Chief AI Officer
  • Eric JahnChief Information Officer
  • Mr. Daniel D. CorcoranSenior VP, General Counsel & Secretary · b. 1967
  • Mr. Ron DiSantisSenior Vice President of Corporate Development

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue163.72M208.51M243.53M286.10M335.64M354.34M385.15M418.84M
Growth (%)-+27.36%+16.79%+17.48%+17.32%+5.57%+8.70%+8.75%
Cost of Revenue71.04M79.77M100.77M111.62M132.58M141.02M154.52M161.13M
Gross Profit92.68M128.74M142.76M174.49M203.07M213.31M230.63M257.71M
Gross Margin56.61%61.74%58.62%60.99%60.50%60.20%59.88%61.53%
Operating Expense97.33M109.13M167.19M160.91M170.55M254.09M232.36M236.70M
Operating Income-4.65M19.61M-24.42M13.58M32.52M-40.77M-1.73M21.02M
Operating Margin-2.84%9.41%-10.03%4.75%9.69%-11.51%-0.45%5.02%
EBITDA32.25M60.41M17.87M58.58M89.00M23.84M72.37M83.91M
EBITDA Margin19.70%28.97%7.34%20.47%26.52%6.73%18.79%20.03%
Net Income-33.26M-8.93M-49.40M-13.27M14.73M-55.36M-12.05M-1.59M
Net Income Margin-20.31%-4.28%-20.28%-4.64%4.39%-15.62%-3.13%-0.38%
R&D10.48M11.63M19.64M20.38M28.20M34.17M37.10M41.04M
R&D as % of Total Revenue6.40%5.58%8.07%7.12%8.40%9.64%9.63%9.80%
Interest Expense27.80M28.00M25.30M16.84M17.77M22.92M21.52M19.74M
Interest Expense % of Total Revenue16.98%13.43%10.39%5.88%5.30%6.47%5.59%4.71%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.05B1.04B1.27B1.51B1.57B1.56B1.58B1.56B
Total Liabilities558.72M545.02M447.27M469.88M493.26M516.30M516.45M493.79M
Total Equity492.77M492.05M822.13M1.04B1.08B1.05B1.06B1.06B
Cash11.68M29.26M271.38M185.80M236.59M234.95M179.18M189.39M
Total Debt408.28M401.38M299.37M308.38M308.13M302.57M311.90M11.40M
Net Debt396.60M372.12M27.99M122.58M71.55M67.62M132.71M-177.99M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.59M38.02M44.81M60.39M92.54M82.75M80.47M96.33M
Investing Cash Flow-73.91M-9.52M-8.61M-269.92M-27.84M-79.55M-112.37M-26.56M
Financing Cash Flow57.30M-8.49M208.21M123.39M-7.36M-9.45M-21.01M-63.99M
Capital Expenditure11.48M9.52M7.94M8.90M12.53M15.32M21.04M26.56M
Free Cash Flow107.00K28.51M36.87M51.49M80.01M67.43M59.42M69.77M
Dividends Paid75.00M703.00K19.88M272.00K----
FCF to OCF0.92%74.97%82.29%85.26%86.46%81.49%73.85%72.43%
Dividend Paid to FCF70093.46%2.47%53.91%0.53%----

Earnings

Report DateDec 31, 2019Dec 14, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 9, 2021Mar 1, 2022May 5, 2022Aug 9, 2022Nov 7, 2022Mar 1, 2023May 8, 2023Aug 9, 2023Nov 8, 2023Feb 29, 2024May 7, 2024Aug 6, 2024Nov 6, 2024Feb 26, 2025May 5, 2025Aug 6, 2025Nov 6, 2025Feb 26, 2026May 11, 2026Aug 4, 2026Nov 5, 2026
EPS Estimate0.000.020.030.050.050.060.090.110.110.120.130.120.130.110.110.100.100.110.130.110.100.110.070.110.060.06
EPS Actual-0.050.030.090.060.030.070.010.110.090.100.160.120.120.110.090.100.070.130.150.140.070.140.050.090.05-
Surprise-50.00%200.00%20.00%-40.00%16.67%-88.89%0.00%-18.18%-16.67%23.08%0.00%-7.69%0.00%-18.18%0.00%-30.00%18.18%19.62%27.27%-30.00%27.27%-28.57%-18.18%-16.67%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.36B
Enterprise Value1.43B
Trailing P/E0.00
Forward P/E27.17
Price / Sales3.22
Price / Book1.36
EPS-0.14
Book Value6.34
Revenue (TTM)421.75M
Gross Profit (TTM)259.83M
EBITDA94.25M
Profit Margin-16.22%
Operating Margin-0.21%
Return on Equity-2.21%
Return on Assets0.77%
Shares Outstanding152.54M
Shares Float111.95M
Beta1.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 11 analystsTarget 8.34
  • Strong Buy
    4
  • Buy
    1
  • Hold
    6

Ownership Breakdown

Institutions
112.93%
Insiders
2.73%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    14.31M9.38%
  • Deerfield Management Co
    7.81M5.12%
  • Haveli Investment Management LLC
    7.40M4.85%
  • Jefferies Financial Group Inc
    6.86M4.50%
  • Dimensional Fund Advisors, Inc.
    6.02M3.95%
  • Vanguard Portfolio Management, LLC
    5.97M3.91%
  • Vanguard Capital Management, LLC
    5.36M3.51%
  • Wasatch Advisors LP
    4.30M2.82%
  • State Street Corp
    3.94M2.58%
  • UBS Group AG
    3.42M2.24%
  • Morgan Stanley - Brokerage Accounts
    3.24M2.12%
  • Teacher Retirement System Of Texas
    2.96M1.94%
  • Fort Washington Investment Advisors Inc
    2.86M1.88%
  • Mackenzie Investments
    2.72M1.78%
  • Millennium Management LLC
    2.56M1.68%
  • Brown Brothers Harriman & Co
    2.51M1.64%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    7.13M4.67%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.72M2.44%
  • iShares Russell 2000 ETF
    2.97M1.95%
  • Vanguard Small Cap Index
    2.68M1.76%